Gilead Sciences (GILD) Q3 FY26 earnings call

Gilead delivered double-digit revenue expansion driven by core HIV momentum and accelerating oncology demand, while navigating near-term cell therapy headwinds. Management raised full-year commercial expectations and framed an expanding pipeline across HIV, oncology, and inflammation to absorb future pricing pressures from Medicare negotiation.